UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

Osteoporosis international, 2018-03, Vol.29 (3), p.685-697

2018

Volltextzugriff (PDF)

Growth Factor Regulation of Fracture Repair

Journal of bone and mineral research, 1999-11, Vol.14 (11), p.1805-1815

1999

Volltextzugriff (PDF)

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

Osteoporosis international, 2007-08, Vol.18 (8), p.1073-1082

2007

Volltextzugriff (PDF)

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

Cancer research (Chicago, Ill.), 2001-06, Vol.61 (11), p.4432-4436

2001

Volltextzugriff (PDF)

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

Current opinion in pharmacology, 2005-12, Vol.5 (6), p.618-625

Kostenuik, Paul J

2005

Volltextzugriff (PDF)

Skeletal muscle adaptations to microgravity exposure in the mouse

Journal of applied physiology (1985), 2003-12, Vol.95 (6), p.2462-2470

2003

Volltextzugriff (PDF)

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss

Journal of dental research, 2018-08, Vol.97 (9), p.1031-1038

2018

Volltextzugriff (PDF)

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

Calcified tissue international, 2008-05, Vol.82 (5), p.361-372

2008

Volltextzugriff (PDF)

Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats

Bone (New York, N.Y.), 2005-07, Vol.37 (1), p.87-95

2005

Volltextzugriff (PDF)

Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I

Journal of bone and mineral research, 1999-01, Vol.14 (1), p.21-31

1999

Volltextzugriff (PDF)

Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease

Osteoporosis international, 2008-05, Vol.19 (5), p.625-635

2008

Volltextzugriff (PDF)

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (4), p.783-787

2000

Volltextzugriff (PDF)

Bone and hormonal changes induced by skeletal unloading in the mature male rat

American journal of physiology: endocrinology and metabolism, 1999-01, Vol.276 (1), p.E62-E69

1999

Volltextzugriff (PDF)

Skeletal unloading inhibits the in vitro proliferation and differentiation of rat osteoprogenitor cells

American journal of physiology: endocrinology and metabolism, 1997-12, Vol.273 (6), p.E1133-E1139

1997

Volltextzugriff (PDF)

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft

Clinical & experimental metastasis, 2004-01, Vol.21 (5), p.381-387

2004

Volltextzugriff (PDF)

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

The Journal of experimental medicine, 2000-08, Vol.192 (4), p.463-474

2000

Volltextzugriff (PDF)

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption

Current pharmaceutical design, 2001-05, Vol.7 (8), p.613-635

2001

Volltextzugriff (PDF)

RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis

Journal of bone and mineral research, 2005-10, Vol.20 (10), p.1756-1765

2005

Volltextzugriff (PDF)

Selective adhesion of osteoblastic cells to different integrin ligands induces osteopontin gene expression

Matrix biology, 2003-05, Vol.22 (3), p.241-249

2003

Volltextzugriff (PDF)

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

Calcified tissue international, 2008-05, Vol.82 (5), p.361-372

2008

Volltextzugriff (PDF)

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

Journal of bone and mineral research, 2009-07, Vol.24 (7), p.1234-1246

2009

Volltextzugriff (PDF)

The effects of osteoprotegerin on the mechanical properties of rat bone

Journal of materials science. Materials in medicine, 2001-07, Vol.12 (7), p.583-588

2001

Volltextzugriff (PDF)

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin

Clinical & experimental metastasis, 1996-01, Vol.14 (1), p.19-26

1996

Volltextzugriff (PDF)

Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats

Journal of bone and mineral research, 2003-05, Vol.18 (5), p.852-858

2003

Volltextzugriff (PDF)

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

Journal of bone and mineral research, 2010-12, Vol.25 (12), p.2647-2656

2010

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(72)

Sprache

Englisch
(72)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(51)
Animals
(50)
Biological And Medical Sciences
(33)
Endocrinology & Metabolism
(28)
Humans
(26)
Male
(26)
Osteoprotegerin
(26)
Rats
(24)
Female
(22)
Mice
(21)
Fundamental And Applied Biological Sciences. Psychology
(20)
Medical Sciences
(17)
Rats, Sprague-Dawley
(15)
Skeleton And Joints
(13)
Vertebrates: Osteoarticular System, Musculoskeletal System
(13)
Bone Density
(12)
Receptors, Tumor Necrosis Factor
(12)
Bone Density - Drug Effects
(11)
Osteoporosis
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

Growth Factor Regulation of Fracture Repair

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

Skeletal muscle adaptations to microgravity exposure in the mouse

Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats

Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I

Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy

Bone and hormonal changes induced by skeletal unloading in the mature male rat

Skeletal unloading inhibits the in vitro proliferation and differentiation of rat osteoprogenitor cells

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption

RANKL is a Marker and Mediator of Local and Systemic Bone Loss in Two Rat Models of Inflammatory Arthritis

Selective adhesion of osteoblastic cells to different integrin ligands induces osteopontin gene expression

Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice

One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

The effects of osteoprotegerin on the mechanical properties of rat bone

Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin

Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

Suchergebnisse filtern